echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > After Fu's five gold standards, he asked, "have scientists in China created a new field in the life sciences?"

    After Fu's five gold standards, he asked, "have scientists in China created a new field in the life sciences?"

    • Last Update: 2019-12-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Professor Gen Sheng Feng, Professor Fu Xinyuan and Dr fan Yichao gave wonderful speeches at the just concluded 2019biotianfu tumor immune Industry University Research Integration Innovation Summit Forum and the 20th Annual Conference of interferon and cytokines The journalists of pharmaceutical intelligence interviewed three experts Professor Gen Sheng Feng works in the Department of Pathology, University of California, San Diego School of medicine He attended the meeting at the invitation of Mr Ni Jian, chairman of the interferon and cytokine Professional Committee In response to Professor Feng's speech about the pathogenic genes of liver cancer, the reporter raised questions to Professor Feng Professor Gen Sheng Feng: is there any better treatment for liver cancer? Professor Gen Sheng Feng: I don't have direct contact with patients, but I still hope my research has clinical application value The application value is divided into two aspects: 1 Can we find a more effective and accurate diagnosis method; 2 Treatment method My point of view is that there is no really good medicine for liver cancer patients Now the most effective is surgical resection, but surgical resection can only be in the early stage When there are several tumors in the liver, this method is not applicable There are also other ways, but in general, they are to cure the symptoms rather than the root causes This is also because of the particularity of the liver The liver is the most important metabolic organ of the human body It has the function of regeneration Half of the liver can grow again after being cut off Also because of these reasons, liver cancer is more complex than other cancers In short, there are pathways leading to cancer and tumor inhibition Now many of our genes may cause cancer when they are activated, but when you inhibit them, they may also cause cancer This is the complexity of liver cancer For this reason, drug or genetic methods are used to block the signal pathway Through research, it is found that sometimes these methods can not only inhibit but also promote the development of cancer cells So now we need to study the pathogenesis of liver cancer Professor Gen Sheng Feng: what are the difficulties in the transformation from basic research to industrial application? Professor Gen Sheng Feng: people who do research want to transform their achievements, and people who do medicine want to find good research achievements But how to match each other is also a matter of cooperation Sincere cooperation is the most important thing If we start with the calculation of mutual utilization, we will not be able to achieve it Everyone should hold the idea of making medicine successful The focus of cooperation is not to make money The purpose of research is to find out the mechanism and research results The purpose of being a company is to make a good product Professor Fu Xinyuan is a well-known international molecular biomedical and biochemical scholar, and also a scholar of the first cusmbea (China US molecular biology biochemistry exchange program) Professor Fu and Professor Gen Sheng Feng are also very good friends The meeting between the two professors at the end of the interview also shows the interesting interaction between scholars Professor Fu Xinyuan, Professor Gen Sheng Feng, and Professor Fu Xinyuan, reporter: how to combine the academic research of pharmaceutical enterprises and academies of Sciences, so that innovative drugs can truly achieve innovation and better development? Professor Fu Xinyuan: China has developed rapidly in the past 40 years, because many overseas students have made a lot of contributions after returning home, but we can not ignore the efforts of traditional enterprises, such as northeast pharmaceutical, North China pharmaceutical, etc Most Chinese pharmaceutical companies, especially traditional pharmaceutical companies, develop and make drugs by their own companies, with very little contact with universities In the past two decades, a large number of returned overseas students have left Roche, Sanofi and other companies, and it is very common to start their own businesses It is very common to teach entrepreneurship in the United States For example, one of my former colleagues at Yale University is now the director of the Department of pharmacology at Yale University He is a very good scientist, with five or six companies Many of the commonly used lung cancer drugs on the market are developed by his company There are still some gap for professors to start businesses in China Many professors just do research Of course, there are companies like Wang Xiaodong, Rao Yi and so on Why not in the past? Entrepreneurship is risky and Chinese people are more cautious With the beginning of everything and new successful examples, more people will do it Generally speaking, I am optimistic about the future At present, pharmaceutical enterprises have reached a new stage The national policy encourages innovation and development Now, entrepreneurship of scientists is gradually forming a trend, and more and more professors are coming to the stage Professor Fu Xinyuan told reporters: one year after putting forward the "five gold standards for innovative drugs", has there been a successful challenge from peers? Professor Fu Xinyuan: maybe not now, maybe in the next ten years The most important and difficult part of these five standards is to have new mechanisms Now I extend a question on the basis of these five gold standards: "have Chinese scientists created a new field in the life sciences?" There is no challenge for Chinese scientists to innovate in the "zerotone" field We need a real "original" Now maybe some lab is doing it, but we don't know When I raise this question, I also stimulate scientists to think and innovate Now there are scientists in small field innovation in China, but they haven't created a new field from the source For example, Professor Zhang Tingdong found that arsenic can treat leukemia, which is a small innovation But what China needs now is zero to one innovation, and we hope more young people will do it Dr Fan Yichao has decades of scientific research and practice in the field of biomedicine, leading the investment in a number of innovative pharmaceutical projects, including viabio, which has successfully landed in Hong Kong stock market At the annual meeting, Dr Fan mentioned the opportunity of pharmaceutical investment under rapid change, and emphasized that the 21st century is the golden age of biomedicine At present, the opportunity for the development of China's biomedical industry is just right In this regard, the following questions were raised by the reporters of Yaozhi Fan Yichao, director of Shengshan asset investment: from the perspective of investment, how will generic and innovative drugs develop? Dr Fan Yichao: in the macro field, China's new drugs are at an initial stage For example, 48 new drugs have been approved, and only 10 of them are from China The newly launched policies of the state, such as "4 + 7" volume procurement, medical insurance catalog adjustment, etc., have a great impact on the generic pharmaceutical enterprises, so the generic pharmaceutical enterprises will face great challenges in recent years Looking forward, there was a research report ten years ago to sort out and rank the Chinese pharmaceutical enterprises of that year In that year, Hengrui ranked in the third echelon according to its size, and in front of it were some large circulation pharmaceutical companies or traditional Chinese pharmaceutical companies But at that time, the R & D ratio of Hengrui was already the first Now, Hengrui is the "first brother" of Chinese pharmaceutical enterprises In fact, its outbreak in recent years is also because it has spent a lot of efforts on R & D investment in the past so many years, and now there are a number of new drugs coming out continuously In general, innovative drugs are also the biggest trend in the future Both the capital market and the national policy conditions have given innovative drug companies great advantages, and the same is true for innovative drugs in Hong Kong stock market and science and technology innovation board For generic drugs, how to develop and survive? There are some big generic companies overseas It is impossible for Chinese pharmaceutical companies to change from generic drugs to innovative drugs for a while, but they hope not to do so many high-level and repeated generic drugs I think there are two requirements for generic drugs One is the selection of varieties Although the volume purchase will have a great impact on generic drugs, there are only a few varieties in the volume purchase and medical insurance catalog, and many other varieties can be selected for development; the second is to raise the threshold, for example, we can't ignore the quality After several rounds of adjustment, there are about 4000 Chinese pharmaceutical enterprises It may be further reduced in the future This adjustment is to reduce waste and create real value Making generic drugs is to make its own characteristics in some varieties, such as dosage form improvement, minimally invasive new, etc In this way, pharmaceutical companies can make some distinctive things while avoiding the high risk of making innovative drugs Dr Fan Yichao told reporters: which disease areas will have the largest market in the next few years for pharmaceutical enterprises to determine the investment value of pharmaceutical projects or investment institutions? Dr Fan Yichao: from the perspective of market size, the three areas of tumor, immune and metabolic diseases will become the largest market There is no doubt that cancer is the largest sector, especially China's anti-cancer drugs have many opportunities First of all, there is a certain gap between China's anti-cancer drugs and overseas, and it is an opportunity to fill the gap Another large number of patients in China will provide valuable clinical data There are also cancer species with Chinese characteristics, such as liver cancer and lung cancer, which are also unique opportunities for Chinese pharmaceutical companies In the field of metabolic diseases, we can see from two aspects: one is the diseases with drugs and treatment means, but the effect of these drugs and treatment means is not good, such as diabetes Now experts believe that it needs a comprehensive metabolic conditioning, not just glucose lowering The other is the disease without medicine The research of scientists on various mechanisms and targets can give some inspiration to pharmaceutical companies In the past, Chinese patients did not pay special attention to autoimmune diseases, but now with the improvement of living standards, patients no longer only pay attention to whether the disease will be fatal, but pay more attention to their own quality of life That's why in the past, Sumeria has sold 20 billion dollars in the world, but only several hundred million yuan in China One is that the price is relatively high, and the Chinese people do not pay so much attention to this disease Now xiumeile has entered the medical insurance, and the price has dropped dramatically Patients will pay more attention to the disease In fact, there are many projects to be done in the field of autoimmune diseases, such as lupus erythematosus, eczema in infants, etc., all of which have development potential Research and development of drugs can be expanded from one indication to many and occupy a larger market Now, because the health care catalog adjustment also focuses on these areas, these areas should be the most marketable direction Reporter: now the biomedical sector is very hot, but the market share is not high Why? Dr Fan Yichao: one is because of the high price, and the other is because of the accessibility of patients' medicines For example, if Chinese pharmaceutical companies do much better in anti-PD-1 antibody, the original research pharmaceutical companies will reduce their prices if they want to enter the Chinese market It is possible that the price will be lower and the drug users will increase, so the proportion of biological drugs will change greatly in the next few years Editor in charge | Jenny tortoise statement: this point of view only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.